In January, a new Idaho law will take effect requiring reform of business practices by pharmacy middlemen — in search of tamping down prescription drug costs. The new law targets pharmacy benefit ...
The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...
The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...
The FTC in a statement said one PBM Vice President acknowledged the strategy allowed the Big Three to continue to “drink down ...
After that, he offers tips about getting a gas credit card and the best way to choose which one to apply for. After the break, Herb goes over an FTC lawsuit against CarShield and what that could mean ...
However, the Federal Trade Commission (FTC) staff has issued a report that focuses on those income claims made by 70 MLM companies. In the report, the FTC staff found many issues with the income ...
For example, CVS Caremark — the largest PBM with 34% market share, according to the Federal Trade Commission (FTC) — is part of the CVS Health Corporation, which also includes the company’s ...
Fake online reviews and testimonials are a headache for small businesses. They hope the FTC can help
The FTC voted unanimously to ban fake reviews, such as those generated with AI technology, and other misleading advertising practices. This includes banning marketers from paying for positive or ...
In July, the Federal Trade Commission (FTC) released a scathing report on the PBM industry that suggests a lawsuit is around the corner. It's a long shot, but in theory, an FTC victory ...
The FTC said it has agreed to a $2.95 million settlement package with Verkada, which includes acknowledgement that Verkada spammed its own customers with junk email and allowed them to be exposed ...
On August 20, 2024, the Federal Trade Commission (FTC) filed a comment letter in support of the Food and Drug Administration’s (FDA’s) June 2024 draft guidance on biosimilar interchangeability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback